Patents by Inventor Amir Masoud Sadaghiani

Amir Masoud Sadaghiani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators
    Patent number: 11919911
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: March 5, 2024
    Assignee: Novartis AG
    Inventors: Sung David C. Kim, Zaixing Li, Chui Lu, Danuta Lubicka, James Neef, Hye-Yeon Park, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
  • Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as Ca1.2 activators
    Patent number: 11453679
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: September 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Thomas Charles Caya, James Neef, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
  • METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS
    Publication number: 20210395261
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.
    Type: Application
    Filed: June 11, 2021
    Publication date: December 23, 2021
    Inventors: Sung David C. Kim, Zaixing Li, Chui Lu, Danuta Lubicka, James Neef, Hye-Yeon Park, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
  • METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS
    Publication number: 20210387995
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.
    Type: Application
    Filed: June 11, 2021
    Publication date: December 16, 2021
    Inventors: Thomas Charles Caya, James Neef, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou